STOCK TITAN

[Form 4] PFIZER INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Pfizer (PFE) reported an insider transaction by Chairman & CEO and Director Albert Bourla on 10/15/2025. The filing shows the acquisition of 25 phantom stock units under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan at a price of $24.39 per unit. Following this transaction, Bourla’s derivative holdings total 731,111 phantom stock units, held directly. Each unit represents one phantom share of common stock and will be settled in cash after separation from service; units may be transferred into an alternative investment account at any time.

Pfizer (PFE) ha riportato una transazione interna da parte del presidente e CEO e direttore Albert Bourla il 15/10/2025. La compilazione mostra l'acquisizione di 25 unità azionarie fantasma ai sensi del Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan a un prezzo di $24.39 per unità. Dopo questa transazione, le partecipazioni derivate di Bourla ammontano a 731.111 unità azionarie fantasma, detenute direttamente. Ogni unità rappresenta una phantom share ordinarie e sarà pagata in contanti al termine del servizio; le unità possono essere trasferite in un conto di investimento alternativo in qualsiasi momento.

Pfizer (PFE) informó una transacción interna por parte del presidente y CEO y director Albert Bourla el 15/10/2025. La recopilación muestra la adquisición de 25 unidades de acciones fantasma bajo el Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan a un precio de $24.39 por unidad. Tras esta transacción, las participaciones derivadas de Bourla totalizan 731,111 unidades fantasma, mantenidas directamente. Cada unidad representa una phantom share común y se liquidará en efectivo tras la separación del servicio; las unidades pueden transferirse a una cuenta de inversión alternativa en cualquier momento.

Pfizer (PFE) 회장 겸 CEO이자 이사인 Albert Bourla의 내부자 거래가 2025년 10월 15일에 보고되었습니다. 제출서에는 25개의 팬텀 주식 단위가 Pfizer Inc.의 비펀딩 연금 및 보충 저축 계획 아래에서 주당 $24.39의 가격으로 취득되었다고 명시되어 있습니다. 이 거래 이후 Bourla의 파생 보유는 총 731,111개의 팬텀 주식 단위로 증가하며 직접 보유 중입니다. 각 단위는 일반 주식의 팬텀 주식을 나타내며 퇴직 시 현금으로 정산되며; 단위는 언제든지 대체 투자 계좌로 이전될 수 있습니다.

Pfizer (PFE) a rapporté une transaction interne du président-directeur général et administrateur Albert Bourla le 15/10/2025. Le dossier indique l'acquisition de 25 unités d'actions fantômes dans le cadre du Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan à un prix de $24,39 par unité. Suite à cette transaction, les positions dérivées de Bourla totalisent 731 111 unités d'actions fantômes, détenues directement. Chaque unité représente une phantom share ordinaire et sera réglée en espèces après la séparation des services; les unités peuvent être transférées sur un compte d'investissement alternatif à tout moment.

Pfizer (PFE) meldete eine Insider-Transaktion des Vorsitzenden & CEO sowie Direktors Albert Bourla am 15.10.2025. Die Einreichung zeigt den Erwerb von 25 Phantomaktien-Einheiten im Rahmen des Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan zu einem Preis von $24,39 pro Einheit. Nach dieser Transaktion belaufen sich Bourlas derivativen Positionen auf insgesamt 731.111 Phantomaktien-Einheiten, die direkt gehalten werden. Jede Einheit repräsentiert eine Phantom-Aktie der Stammaktien und wird cash settled nach Beendigung der Beschäftigung; die Einheiten können jederzeit auf ein alternatives Investmentkonto übertragen werden.

فايزر (PFE) أبلغت عن صفقة داخلية من قبل رئيس مجلس الإدارة والمدير التنفيذي والسياق Albert Bourla في 15/10/2025. تُظهر الإيداع شراء 25 وحدة أسهم وهمية بموجب خطة Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan بسعر $24.39 للوحدة. بعد هذه المعاملة، تبلغ الحصص المشتقة لبورلا إجمالاً 731,111 وحدة أسهم وهمية، تحتفظ مباشرة. تمثل كل وحدة أسهم وهمية من الأسهم العادية وسيتم تسويتها نقداً بعد الانفصال عن الخدمة؛ يمكن نقل الوحدات إلى حساب استثماري بديل في أي وقت.

辉瑞 (PFE) 总裁兼CEO兼董事 Albert Bourla 于 2025/10/15 披露了一笔内部人交易。该披露显示在 Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan 框架下以每单位 $24.39 的价格购买了 25 份虚拟股票单位。此次交易后, Bourla 的衍生持股总额为 731,111 份虚拟股票单位,直接持有。每单位代表普通股的一份虚拟股,分离服务后将 以现金结算;单位可随时转入其他投资账户。

Positive
  • None.
Negative
  • None.

Insights

Small cash-settled award; administrative and non-dilutive.

Albert Bourla reported acquiring 25 phantom stock units at $24.39 on 10/15/2025, bringing total derivative holdings to 731,111 units. These units are part of a deferred compensation plan.

Because the units are settled in cash after separation, they do not involve share issuance and are typically non-dilutive to common shareholders. The reported quantity is small relative to outstanding equity.

The mechanics and timing are defined by plan terms; actual impact depends on future service and separation events as disclosed in subsequent filings.

Pfizer (PFE) ha riportato una transazione interna da parte del presidente e CEO e direttore Albert Bourla il 15/10/2025. La compilazione mostra l'acquisizione di 25 unità azionarie fantasma ai sensi del Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan a un prezzo di $24.39 per unità. Dopo questa transazione, le partecipazioni derivate di Bourla ammontano a 731.111 unità azionarie fantasma, detenute direttamente. Ogni unità rappresenta una phantom share ordinarie e sarà pagata in contanti al termine del servizio; le unità possono essere trasferite in un conto di investimento alternativo in qualsiasi momento.

Pfizer (PFE) informó una transacción interna por parte del presidente y CEO y director Albert Bourla el 15/10/2025. La recopilación muestra la adquisición de 25 unidades de acciones fantasma bajo el Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan a un precio de $24.39 por unidad. Tras esta transacción, las participaciones derivadas de Bourla totalizan 731,111 unidades fantasma, mantenidas directamente. Cada unidad representa una phantom share común y se liquidará en efectivo tras la separación del servicio; las unidades pueden transferirse a una cuenta de inversión alternativa en cualquier momento.

Pfizer (PFE) 회장 겸 CEO이자 이사인 Albert Bourla의 내부자 거래가 2025년 10월 15일에 보고되었습니다. 제출서에는 25개의 팬텀 주식 단위가 Pfizer Inc.의 비펀딩 연금 및 보충 저축 계획 아래에서 주당 $24.39의 가격으로 취득되었다고 명시되어 있습니다. 이 거래 이후 Bourla의 파생 보유는 총 731,111개의 팬텀 주식 단위로 증가하며 직접 보유 중입니다. 각 단위는 일반 주식의 팬텀 주식을 나타내며 퇴직 시 현금으로 정산되며; 단위는 언제든지 대체 투자 계좌로 이전될 수 있습니다.

Pfizer (PFE) a rapporté une transaction interne du président-directeur général et administrateur Albert Bourla le 15/10/2025. Le dossier indique l'acquisition de 25 unités d'actions fantômes dans le cadre du Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan à un prix de $24,39 par unité. Suite à cette transaction, les positions dérivées de Bourla totalisent 731 111 unités d'actions fantômes, détenues directement. Chaque unité représente une phantom share ordinaire et sera réglée en espèces après la séparation des services; les unités peuvent être transférées sur un compte d'investissement alternatif à tout moment.

Pfizer (PFE) meldete eine Insider-Transaktion des Vorsitzenden & CEO sowie Direktors Albert Bourla am 15.10.2025. Die Einreichung zeigt den Erwerb von 25 Phantomaktien-Einheiten im Rahmen des Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan zu einem Preis von $24,39 pro Einheit. Nach dieser Transaktion belaufen sich Bourlas derivativen Positionen auf insgesamt 731.111 Phantomaktien-Einheiten, die direkt gehalten werden. Jede Einheit repräsentiert eine Phantom-Aktie der Stammaktien und wird cash settled nach Beendigung der Beschäftigung; die Einheiten können jederzeit auf ein alternatives Investmentkonto übertragen werden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BOURLA ALBERT

(Last) (First) (Middle)
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY

(Street)
NEW YORK NY 10001-2192

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
PFIZER INC [ PFE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chairman & CEO
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Phantom Stock Units SSP (1) 10/15/2025 A 25 (2) (2) Common Stock 25 $24.39 731,111 D
Explanation of Responses:
1. Each unit represents one phantom share of common stock.
2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
/s/ Shanice A. Reid, by power of atty., for Albert Bourla 10/17/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pfizer (PFE) report in this Form 4?

Albert Bourla acquired 25 phantom stock units on 10/15/2025 at $24.39 per unit.

How many derivative units does Albert Bourla hold after the transaction?

He holds 731,111 phantom stock units directly after the reported transaction.

What are phantom stock units in this context?

Each unit represents one phantom share of common stock and is settled in cash following separation from service.

Under which plan were the units acquired?

They were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Do these phantom stock units dilute existing Pfizer shareholders?

They are cash-settled, which typically does not result in share issuance and therefore is non-dilutive.

Can the units be moved between investment options?

Yes. The units may be transferred into an alternative investment account at any time.
Pfizer

NYSE:PFE

PFE Rankings

PFE Latest News

PFE Latest SEC Filings

PFE Stock Data

137.76B
5.68B
0.07%
67.08%
1.82%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
NEW YORK